139 related articles for article (PubMed ID: 20303211)
21. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms.
Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M
Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
23. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y
Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732
[TBL] [Abstract][Full Text] [Related]
24. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
25. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses.
Fleming JS; Beaugié CR; Haviv I; Chenevix-Trench G; Tan OL
Mol Cell Endocrinol; 2006 Mar; 247(1-2):4-21. PubMed ID: 16297528
[TBL] [Abstract][Full Text] [Related]
26. Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Pectasides D; Papaxoinis G; Fountzilas G; Aravantinos G; Bamias A; Pavlidis N; Kalofonos HP; Timotheadou E; Samantas E; Briasoulis E; Skarlos DV; Economopoulos T; Dimopoulos MA;
Anticancer Res; 2009 Feb; 29(2):745-51. PubMed ID: 19331231
[TBL] [Abstract][Full Text] [Related]
27. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
28. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
29. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
30. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
Demeter A; Várkonyi T; Csapó Z; Szánthó A; Oláh J; Papp Z
Magy Onkol; 2004; 48(3):259-65. PubMed ID: 15520877
[TBL] [Abstract][Full Text] [Related]
31. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
32. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
33. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
34. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic factors of epithelial ovarian cancer in young women].
Zhang R; Wu LY; Zhang WH; Li HJ; Li SM; Liu LY
Zhonghua Zhong Liu Za Zhi; 2003 May; 25(3):264-7. PubMed ID: 12839691
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
38. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).
Barnholtz-Sloan JS; Morris R; Malone JM; Munkarah AR
Gynecol Oncol; 2004 May; 93(2):506-12. PubMed ID: 15099970
[TBL] [Abstract][Full Text] [Related]
39. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
40. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.
Bignotti E; Todeschini P; Calza S; Falchetti M; Ravanini M; Tassi RA; Ravaggi A; Bandiera E; Romani C; Zanotti L; Tognon G; Odicino FE; Facchetti F; Pecorelli S; Santin AD
Eur J Cancer; 2010 Mar; 46(5):944-53. PubMed ID: 20060709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
